These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32495917)

  • 1. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
    Ding JG; Li J; Hong L; Yu XQ; Ye EL; Sun GQ; Zhang XX; Chen L; Sun QF
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5788-5796. PubMed ID: 32495917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
    Vargas M; Servillo G; Einav S
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
    Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
    J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
    Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
    J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
    Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19.
    Chen X; Zhu B; Hong W; Zeng J; He X; Chen J; Zheng H; Qiu S; Deng Y; Chan JCN; Wang J; Zhang Y
    Int J Infect Dis; 2020 Sep; 98():252-260. PubMed ID: 32619760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study.
    Shi D; Wu W; Wang Q; Xu K; Xie J; Wu J; Lv L; Sheng J; Guo J; Wang K; Fang D; Li Y; Li L
    J Infect Dis; 2020 Aug; 222(6):910-918. PubMed ID: 32614392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and treatment of COVID-19 patients in northeast Chongqing.
    Wan S; Xiang Y; Fang W; Zheng Y; Li B; Hu Y; Lang C; Huang D; Sun Q; Xiong Y; Huang X; Lv J; Luo Y; Shen L; Yang H; Huang G; Yang R
    J Med Virol; 2020 Jul; 92(7):797-806. PubMed ID: 32198776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin manifestations associated with the new coronavirus SARS-CoV-2 disease.
    Redondo-Sendino Á; González Sánchez IC; de Victoria Fernández B
    Med Clin (Barc); 2020 Nov; 155(9):414-415. PubMed ID: 32873395
    [No Abstract]   [Full Text] [Related]  

  • 12. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
    Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
    Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.
    Yuan J; Zou R; Zeng L; Kou S; Lan J; Li X; Liang Y; Ding X; Tan G; Tang S; Liu L; Liu Y; Pan Y; Wang Z
    Inflamm Res; 2020 Jun; 69(6):599-606. PubMed ID: 32227274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
    Stalder G; Alberio L
    Blood; 2020 Aug; 136(7):915. PubMed ID: 32790855
    [No Abstract]   [Full Text] [Related]  

  • 17. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
    Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2.
    Zhang H; Xie C; Huang Y
    J Thorac Oncol; 2020 May; 15(5):e63-e64. PubMed ID: 32147577
    [No Abstract]   [Full Text] [Related]  

  • 19. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
    Owa AB; Owa OT
    J Microbiol Immunol Infect; 2020 Oct; 53(5):674-675. PubMed ID: 32474026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
    Young BE; Ong SWX; Kalimuddin S; Low JG; Tan SY; Loh J; Ng OT; Marimuthu K; Ang LW; Mak TM; Lau SK; Anderson DE; Chan KS; Tan TY; Ng TY; Cui L; Said Z; Kurupatham L; Chen MI; Chan M; Vasoo S; Wang LF; Tan BH; Lin RTP; Lee VJM; Leo YS; Lye DC;
    JAMA; 2020 Apr; 323(15):1488-1494. PubMed ID: 32125362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.